BRIEF-Recce Pharmaceuticals Receives Approval For Additional Phase II Trial Of RECCE® 327 Topical Gel For Diabetic Foot Infections

Reuters
23 Apr
BRIEF-Recce Pharmaceuticals Receives Approval For Additional Phase II Trial Of RECCE® 327 Topical Gel For Diabetic Foot Infections

April 23 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:

  • RECCE PHARMACEUTICALS RECEIVES APPROVAL FOR ADDITIONAL PHASE II TRIAL OF RECCE® 327 TOPICAL GEL FOR DIABETIC FOOT INFECTIONS

Source text: ID:nGNX8Z40jC

Further company coverage: RCE.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10